110 compounds that exhibited more than 50% reduced viability in either control or Brca2-KO KPC-mT3 cells were chosen for concentration response curve (CRC) experiments (Fig. 1B and Supplementary file 2). Here, BRCA2 is linked to colorectal carcinoma.